Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 6201-6210 Newer>

The Motley Fool February 19, 2010 Brian Orelli	Breathe Deep. It Might Not Be That Bad. The FDA strikes down asthma drugs, but will doctors buy in?
Chemistry World February 18, 2010 Matt Wilkinson	Merck joins the cost-cutting crowd Following its merger with Schering-Plough, US drug giant Merck & Co. has announced a 'merger restructuring plan' that in its first phase will see 17,500 jobs cut.
The Motley Fool February 18, 2010 Brian Orelli	Still Restless for an Approval The FDA is like a box of chocolates: You never know what you're going to get -- rejection or acceptance.
The Motley Fool February 18, 2010 Brian Orelli	Gilead Shareholders Are Whistling a Happy Tune Full data from the company's HIV quad pill show no major issues.
The Motley Fool February 17, 2010 Brian Orelli	Execute Well or You're Out Genzyme needs to show investors that it can rebuild.
The Motley Fool February 17, 2010 Brian Orelli	This Is Not Your Generic Cash Production Teva's generating cash and knows how to use it.
The Motley Fool February 17, 2010 Brian Orelli	$1.24 Billion Deal. Shares Fall 9%. That Makes Sense. Rigel Pharmaceuticals signed up AstraZeneca to take over development of its phase 2 rheumatoid arthritis drug, R788, with more than $1.24 billion in potential payments, and the shares fell more than 9%.
The Motley Fool February 16, 2010 Brian Orelli	Merck Gets a Pass, for Now Its first quarter looks promising, but not as good as could be hoped.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool February 12, 2010 Brian Orelli	Don't Ignore This Potential Blockbuster Five trials later, Roche's diabetes drug taspoglutide seems like a winner.
<Older 6201-6210 Newer> Return to current articles.